¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2023 Çѱ¹¸Á¸·ÇÐȸ ÇÏ°èÇмú´ëȸ (2ÀÏÂ÷) : 2023-06-17

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2023 Çѱ¹¸Á¸·ÇÐȸ ÇÏ°èÇмú´ëȸ (2ÀÏÂ÷) : 2023-06-17
±³À°ÀÏÀÚ : 2023-06-17
±³À°Àå¼Ò : ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ

±³À°ÁÖÁ¦ : 2023 Çѱ¹¸Á¸·ÇÐȸ ÇÏ°èÇмú´ëȸ (2ÀÏÂ÷)

ÁÖÃÖ±â°ü : ´ëÇѾȰúÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Çѱ¹¸Á¸·ÇÐȸ

´ã´çÀÚ : ¹ÚÀ±Á¤
¿¬¶ôó : 02-471-6520

À̸ÞÀÏ : retina@retina.or.kr

±³À°Á¾·ù : ¾È°ú

Âü¼®¿¹»óÀÎ : 150¸í
Èñ¸ÁÆòÁ¡ : 2Á¡

Áö¿ª : ´ë±¸±¤¿ª½Ã
±³À°½Ã°£ : 2 ½Ã°£ 32ºÐ

¼¼ºÎ¼ö°­·á : 50,000¿ø  

ºñ°í


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 08:00~08:07 [ÃʷϹßÇ¥] À¯Àü¼º ¸Á¸·ÁúȯÀÇ Áø´ÜÀ» À§ÇÑ Next-Generation Sequencing ù°æÇè ³²±âÅÂ(Á¦ÁÖ´ë)

±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 08:07~08:14 [ÃʷϹßÇ¥] Clinical diagnosis and characteristics in Korean patients with RPE65-associated retinal dystrophy ±è»óÁø(¼º±Õ°ü´ë)

±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 08:14~08:21 [ÃʷϹßÇ¥] Detection of Alu insertion in RP1 gene in patients with retinitis pigmentosa using whole genome sequencing ÀÌÁÖ¿ë(¼­¿ï¾Æ»êº´¿ø)

±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 08:21~08:28 [ÃʷϹßÇ¥] Whole Genome Sequencing for Inherited Retinal Diseases in Korea¡¯s National Project of Bio Big Data ÁÖ±¤½Ä(¼­¿ï´ë)

±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 08:28~08:35 [ÃʷϹßÇ¥] Genetic Characteristics of Korean Inherited Retinal Disease patients: a Multicenter Study by Korean Eye Gene Consortium ¹è¼®Çö(Çѱæ¾È°úº´¿ø)

±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 08:35~08:42 [ÃʷϹßÇ¥] OCT biomarkers in choroideremia and choroideremia carriers ÀÌÀº°æ(¼­¿ï´ë)

ÈÞ½Ä 06¿ù 17ÀÏ 08:42~08:55 Break time ()

±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 08:55~09:04 [ÃʷϹßÇ¥] Influence of Internal limiting membrane peeling during idiopathic epiretinal membrane removal: A prospective study ¹Ú¿îö(¼­¿ï´ë)

±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 09:04~09:13 [ÃʷϹßÇ¥] What is the ideal surgery for RRD in young patients?: T-shape small incision SB ±èÈ«±Ô(´Ü±¹´ë)

±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 09:13~09:22 [ÃʷϹßÇ¥] Factors triggering epiretinal membrane development and progression before and after par plana vitrectomy for rhegmatogenous retinal detachment ¾ÈÁöÀ±(¼­¿ï´ë)

±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 09:22~09:31 [ÃʷϹßÇ¥] º¯ÇüµÈ  LÀÚ ÇüÅÂÀÇ È²¹Ýµ¹¸¢¼ú : pearls and tips ±èÁß°ï(¼­¿ï¾Æ»êº´¿ø)

±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 09:31~09:40 [ÃʷϹßÇ¥] Àΰø¼öÁ¤Ã¼Å»±¸ ȯÀÚ¿¡¼­ ½ÃÇàÇÏ´Â ³ªÀÇ ¹«ºÀÇÕÀΰø¼öÁ¤Ã¼°ø¸·°íÁ¤¼ú(¾ß¸¶³×¼ú±â) Áõ·Ê ¸®ºä ÀÌÁ¤È£(Àߺ¸´Â¾È°ú)

±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 09:40~09:49 [ÃʷϹßÇ¥] º´ÇÕ¼ö¼úÁß ÃÊÀ½ÆÄ À¯È­¼ú°ú Àΰø¼öÁ¤Ã¼»ðÀÔ¼ú±â¿¡ ´ëÇÑ ¼±ÅûçÇ× ±èÁ¾¿í(¿ì¸®¾È°ú)

ÈÞ½Ä 06¿ù 17ÀÏ 09:49~10:00 Break time ()

±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 10:00~10:07 [ÃʷϹßÇ¥] Changes of Retinal Nonperfusion in Diabetic Macular Edema Following Anti-VEGF Loading Injections ±è±â¿µ(°æÈñ´ë)

±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 10:07~10:14 [ÃʷϹßÇ¥] RAP: The Progressive Disease ±èÀçÈÖ(±è¾È°úº´¿ø)

±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 10:14~10:21 [ÃʷϹßÇ¥] Long-term efficacy and safety of intravitreal brolucizumab injections for neovascular age-related macular degeneration: a multicenter retrospective real-world study ¿ì¼¼ÁØ(¼­¿ï´ë)

±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 10:21~10:28 [ÃʷϹßÇ¥] Phase III Randomized Clinical Trial Comparing SB15 with Reference Aflibercept in Neovascular Age-Related Macular Degeneration: 56-Week Results »ç°ø¹Î(¿µ³²´ë)

±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 10:28~10:35 [ÃʷϹßÇ¥] Delayed anti-vascular endothelial growth factor (VEGF) treatment in the patients with neovascular age-related macular degeneration during the coronavirus disease pandemic: 2-year follow-up °­°æÅÂ(°è¸í´ë)

±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 10:35~10:42 [ÃʷϹßÇ¥] Early outer nuclear layer recovery during the aflibercept loading correlates to 1-year visual outcome in type 1 choroidal neovascularization of neovascular age-related macular degeneration ¼­ÀÇÁ¾(ÃæºÏ´ë)

±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 10:42~10:49 [ÃʷϹßÇ¥] Quantitative analysis of change in choriocapillary flow after photodynamic therapy in central serous chorioretinopathy ±è·¡¿µ(°¡Å縯´ë)

±³À°½Ã°£ 06¿ù 17ÀÏ ÀÎÅͺҰíÈ£ÅÚ ÄÁº¥¼Ç2Ȧ 10:49~10:56 [ÃʷϹßÇ¥] Macular Microvasculature in Diabetic Retinopathy with Systemic Hypertension À̹οì(°Ç¾ç´ë)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2023 Çѱ¹¸Á¸·ÇÐȸ ÇÏ°èÇмú´ëȸ (2ÀÏÂ÷) : 2023-06-17""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2023 KODA ±Û·Î¹ú Æ÷·³(Çѱ¹Àå±âÁ¶Á÷±âÁõ¿ø&´ëÇѽŰæ°úÇÐȸ) : 2023-06-17
´ÙÀ½±Û 2023³â Á¦6ȸ ´ëÇÑÁßȯÀÚÀçÈ°ÇÐȸ Áý´ãȸ : 2023-06-17
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20925 ÀüºÏ Á¦ 53Â÷ ´ëÇѳëÀκ´ÇÐȸ È£³²Áöȸ ÇмúÁý´äȸ : 2024-07-27 0 50 2024-05-28
20924 ¼­¿ï 2024 Á¦27ȸ ´ëÇѾȸ鼺ÇüÀç°ÇÇÐȸ Ãá°è Çмú´ëȸ : 2024-07-21 0 44 2024-05-28
20923 °æ±â 2024³â ÀÏ»ê¹éº´¿ø Á¤Çü¿Ü°ú ½ÉÆ÷Áö¾ö : 2024-07-21 0 44 2024-05-28
20922 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(2ÀÏÂ÷) : 2024-07-20 0 52 2024-05-28
20921 ¼­¿ï Á¦33Â÷ ´ç´¢º´ ¿¬±¸ ÇÏ°è¿öÅ©¼¥ : 2024-07-20 0 39 2024-05-28
20920 ¼­¿ï ´ëÇÑÁ¾¾ç³»°úÇÐȸ Recent updates in GU Cancers 2024 : 2024-07-19 0 76 2024-05-28
20919 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(1ÀÏÂ÷) : 2024-07-19 0 29 2024-05-28
20918 ¼­¿ï [¿Â¶óÀÎ] Áø´Ü¿ë ¹æ»ç¼± ¾ÈÀü°ü¸®Ã¥ÀÓÀÚ ¼±ÀÓ±³À° : 2024-07-14 0 45 2024-05-28
20917 °æºÏ 2024³â ´ëÇÑ°ñ´Ù°øÁõÇÐȸ ¿µ³² ¿¬¼ö°­Á : 2024-07-14 0 39 2024-05-28
20916 °æ±â ÀÎÁ¦´ëÇб³ ÀÏ»ê¹éº´¿ø ¼ÒÈ­±â³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-07-13 0 47 2024-05-28
20915 °æ±â 2024³â ÀÇÁ¤ºÎÀ»Áö´ëÇб³º´¿ø Á¦1ȸ ½Å°æ°ú °³¿øÀÇ ¿¬¼ö±³À° : 2024-07-13 0 48 2024-05-28
20914 ºÎ»ê Á¦6ȸ ºÎ»ê¼º¸ðº´¿ø ¼Ò¾Æû¼Ò³â°ú ½ÉÆ÷Áö¾ö : 2024-07-13 0 33 2024-05-28
20913 ¼­¿ï 2024 ´ëÇѽŰ泻ºÐºñ¿¬±¸È¸ ¿¬¼ö°­Á : 2024-07-13 0 37 2024-05-28
20912 ¼­¿ï ÀºÆò±¸ÀÇ»çȸ Á¦3Â÷¿¬¼ö±³À° : 2024-07-11 0 44 2024-05-28
20911 ¼­¿ï (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-08 0 46 2024-05-28
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷